Saamya Biotech (India) Limited is an India-based biotechnology company. The Company's principal activity is trading of active pharmaceutical ingredients (API). The Company is engaged in the business of research and development of biotechnology products. The Company focuses on manufacturing and marketing of biopharmaceuticals and recombinant protein products of medical and industrial fields. The Company focuses on setting up of manufacturing facilities with an aggregate installed capacity of 342 kilograms per annum of bulk APIs of biopharmaceuticals. The Company also focuses on manufacturing Daunomycin, Hyaluronic acid (Pharma Grade), Tacrolimus, Rapamycin, Cyclosporin A, Probiotics, Lysergic Acid, Mycophenolic Acid, Clavulenic Acid, Vancomycin, Co-Enzyme Q10, Interferon B and Monoclonal Antibodies (anti-cancer). The Company intends to manufacture biopharmaceuticals in its plant located in Hyderabad, India.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.